Angiotensin-Converting Enzyme Inhibitors Prevent Liver-Related Events in NAFLD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease
Hepatology 2022 Aug 01;76(2)469-482, X Zhang, GL Wong, TC Yip, YK Tse, LY Liang, VW Hui, H Lin, GL Li, JC Lai, HL Chan, VW WongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.